Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for STRATA Skin Sciences (SSKN) over the last 14 years, with Q3 2025 value amounting to $7.1 million.

  • STRATA Skin Sciences' Cash & Equivalents rose 19.82% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 19.82%. This contributed to the annual value of $7.3 million for FY2024, which is 703.12% up from last year.
  • Latest data reveals that STRATA Skin Sciences reported Cash & Equivalents of $7.1 million as of Q3 2025, which was up 19.82% from $6.0 million recorded in Q2 2025.
  • STRATA Skin Sciences' 5-year Cash & Equivalents high stood at $13.0 million for Q3 2021, and its period low was $2.8 million during Q1 2023.
  • Its 5-year average for Cash & Equivalents is $7.9 million, with a median of $7.1 million in 2023.
  • As far as peak fluctuations go, STRATA Skin Sciences' Cash & Equivalents tumbled by 7413.71% in 2023, and later skyrocketed by 8538.05% in 2024.
  • STRATA Skin Sciences' Cash & Equivalents (Quarter) stood at $12.6 million in 2021, then plummeted by 56.83% to $5.4 million in 2022, then rose by 24.84% to $6.8 million in 2023, then increased by 7.03% to $7.3 million in 2024, then dropped by 2.55% to $7.1 million in 2025.
  • Its Cash & Equivalents stands at $7.1 million for Q3 2025, versus $6.0 million for Q2 2025 and $6.5 million for Q1 2025.